EVELO BIOSCIENCES INC's ticker is EVLO and the CUSIP is 299734103. A total of 38 filers reported holding EVELO BIOSCIENCES INC in Q3 2018. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $0 | – | 14 | 0.0% | 0.00% | – |
| Q4 2022 | $0 | – | 14 | -90.3% | 0.00% | – |
| Q3 2022 | $0 | -100.0% | 144 | -93.7% | 0.00% | – |
| Q1 2022 | $7,000 | -82.5% | 2,271 | -66.0% | 0.00% | – |
| Q4 2021 | $40,000 | +73.9% | 6,679 | +102.6% | 0.00% | – |
| Q3 2021 | $23,000 | -20.7% | 3,296 | +58.5% | 0.00% | – |
| Q2 2021 | $29,000 | +61.1% | 2,079 | +23.7% | 0.00% | – |
| Q1 2021 | $18,000 | +38.5% | 1,681 | +55.8% | 0.00% | – |
| Q4 2020 | $13,000 | – | 1,079 | +2469.0% | 0.00% | – |
| Q3 2020 | $0 | – | 42 | +121.1% | 0.00% | – |
| Q2 2020 | $0 | – | 19 | -88.3% | 0.00% | – |
| Q1 2020 | $0 | -100.0% | 163 | -87.9% | 0.00% | – |
| Q4 2019 | $5,000 | +400.0% | 1,343 | +685.4% | 0.00% | – |
| Q3 2019 | $1,000 | 0.0% | 171 | +242.0% | 0.00% | – |
| Q4 2018 | $1,000 | -66.7% | 50 | -78.1% | 0.00% | – |
| Q3 2018 | $3,000 | – | 228 | +1800.0% | 0.00% | – |
| Q2 2018 | $0 | – | 12 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Mayo Clinic | 484,953 | $1,823,000 | 4.61% |
| Flagship Pioneering Inc. | 18,233,403 | $68,558,000 | 3.21% |
| HARBOURVEST PARTNERS LLC | 1,763,505 | $6,622,000 | 3.20% |
| Alphabet Inc. | 1,060,495 | $3,982,000 | 0.26% |
| Larson Financial Group LLC | 20,042 | $75,000 | 0.05% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 133,500 | $501,000 | 0.01% |
| CREDIT SUISSE AG/ | 1,500,117 | $5,633,000 | 0.01% |
| FMR LLC | 3,220,853 | $12,094,000 | 0.00% |
| VICTORY CAPITAL MANAGEMENT INC | 177,856 | $668,000 | 0.00% |
| Legal & General Group Plc | 1,522 | $6,000 | 0.00% |